Literature DB >> 2445344

Inhibition of HIV-associated reverse transcriptase by sugar-modified derivatives of thymidine 5'-triphosphate in comparison to cellular DNA polymerases alpha and beta.

E Matthes1, C Lehmann, D Scholz, M von Janta-Lipinski, K Gaertner, H A Rosenthal, P Langen.   

Abstract

The sugar-modified dTTP analogues 2',3'-didehydro-2',3'-dideoxy-thymidine 5'-triphosphate (ddeTTP), 2',3'-dideoxythymidine 5'-triphosphate (ddTTP), 3'-fluorothymidine 5'-triphosphate (FdTTP), and 3'-azidothymidine 5'-triphosphate (N3dTTP) are demonstrated to be very effective and selective inhibitors of the HIV-associated reverse transcriptase (HIV-RT). This conclusion is based on a comparison of the ID50 values of the compounds for the HIV-RT (ranging from 0.03 microM for ddeTTP to 0.1 microM for ddTTP) and the cellular DNA polymerase alpha (greater than 200 microM). DNA polymerase beta is partially affected by N3dTTP (ID50 = 31 microM) and by the other analogues (ID50 = 1-2.2 microM). FdTTP has proved as effective as N3dTTP (ID50 = 0.05 microM) in suppressing the HIV-RT activity. Kinetic analysis revealed for both dTTP analogues a competitive type of inhibition and the same K1 values (about 0.05 microM).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2445344     DOI: 10.1016/0006-291x(87)91078-3

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

1.  Comparative inhibition of hepatitis B virus DNA polymerase and cellular DNA polymerases by triphosphates of sugar-modified 5-methyldeoxycytidines and of other nucleoside analogs.

Authors:  E Matthes; K Reimer; M von Janta-Lipinski; H Meisel; C Lehmann
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

Review 2.  Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription.

Authors:  E J Arts; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

3.  A study of deoxyribonucleotide metabolism and its relation to DNA synthesis. Supercomputer simulation and model-system analysis.

Authors:  F Heinmets; R H Leary
Journal:  Cell Biophys       Date:  1991-06

4.  Azidothymidine triphosphate is an inhibitor of both human immunodeficiency virus type 1 reverse transcriptase and DNA polymerase gamma.

Authors:  H König; E Behr; J Löwer; R Kurth
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

5.  Induction of the SOS response in Escherichia coli by azidothymidine and dideoxynucleosides.

Authors:  S W Mamber; K W Brookshire; S Forenza
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 6.  Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection.

Authors:  A P Lea; D Faulds
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

7.  A photolabile 2',3'-dideoxyuridylate analog bearing an aryl(trifluoromethyl)diazirine moiety: photoaffinity labeling of HIV-1 reverse transcriptase.

Authors:  T Yamaguchi; M Saneyoshi
Journal:  Nucleic Acids Res       Date:  1996-09-01       Impact factor: 16.971

8.  Potent inhibition of hepatitis B virus production in vitro by modified pyrimidine nucleosides.

Authors:  E Matthes; P Langen; M von Janta-Lipinski; H Will; H C Schröder; H Merz; B E Weiler; W E Müller
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

9.  Nuclear and mitochondrial changes of muscle fibers in AIDS after treatment with high doses of zidovudine.

Authors:  J M Schröder; M Bertram; R Schnabel; U Pfaff
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

10.  NCI-sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: safety studies.

Authors:  Alexander M Spence; Mark Muzi; Jeanne M Link; John M Hoffman; Janet F Eary; Kenneth A Krohn
Journal:  Mol Imaging Biol       Date:  2008-06-10       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.